On Tuesday, MiNK Therapeutics Inc (NASDAQ: INKT) opened lower -4.52% from the last session, before settling in for the closing price of $0.71. Price fluctuations for INKT have ranged from $0.71 to $1.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.00% over the last five years. Company’s average yearly earnings per share was noted 47.61% at the time writing. With a float of $10.02 million, this company’s outstanding shares have now reached $34.60 million.
The firm has a total of 31 workers. Let’s measure their productivity. In terms of profitability, gross margin is 144.62%, operating margin of 0.15%, and the pretax margin is 0.15%.
MiNK Therapeutics Inc (INKT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of MiNK Therapeutics Inc is 74.67%, while institutional ownership is 2.27%. The most recent insider transaction that took place on Oct 13 ’23, was worth 21,310. In this transaction 10% Owner of this company bought 19,373 shares at a rate of $1.10, taking the stock ownership to the 21,772,434 shares. Before that another transaction happened on Oct 12 ’23, when Company’s 10% Owner bought 3,173 for $1.10, making the entire transaction worth $3,488. This insider now owns 21,753,061 shares in total.
MiNK Therapeutics Inc (INKT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 47.61% per share during the next fiscal year.
MiNK Therapeutics Inc (NASDAQ: INKT) Trading Performance Indicators
Check out the current performance indicators for MiNK Therapeutics Inc (INKT). In the past quarter, the stock posted a quick ratio of 0.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.49, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.42 in one year’s time.
Technical Analysis of MiNK Therapeutics Inc (INKT)
Analysing the last 5-days average volume posted by the [MiNK Therapeutics Inc, INKT], we can find that recorded value of 0.13 million was better than the volume posted last year of 98146.0. As of the previous 9 days, the stock’s Stochastic %D was 27.12%. Additionally, its Average True Range was 0.04.
During the past 100 days, MiNK Therapeutics Inc’s (INKT) raw stochastic average was set at 16.12%, which indicates a significant decrease from 50.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.60% in the past 14 days, which was lower than the 52.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7946, while its 200-day Moving Average is $0.9135. Now, the first resistance to watch is $0.7420. This is followed by the second major resistance level at $0.8060. The third major resistance level sits at $0.8920. If the price goes on to break the first support level at $0.5920, it is likely to go to the next support level at $0.5060. Should the price break the second support level, the third support level stands at $0.4420.
MiNK Therapeutics Inc (NASDAQ: INKT) Key Stats
There are currently 34,728K shares outstanding in the company with a market cap of 26.81 million. Presently, the company’s annual sales total 0 K according to its annual income of -22,460 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -2,700 K.
